FEATURED MANUSCRIPTS
Cardiac Progenitors Induced from Human Induced Pluripotent Stem Cells with Cardiogenic Small Molecule Effectively Regenerate Infarcted Hearts
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
Cardiac progenitor cells (CPCs) being multipotent offer a promising source for cardiac repair due to their ability to proliferate and multiply into cardiac lineage cells. Here, we explored a novel strategy for human CPCs generation from human induced pluripotent stem cells (hiPSCs) using a cardiogenic small molecule, isoxazole (ISX-9) and
Cardiac progenitor cells (CPCs) being multipotent offer a promising source for cardiac repair due to their ability to proliferate and multiply into cardiac lineage cells. Here, we explored a novel strategy for human CPCs generation from human induced pluripotent stem cells (hiPSCs) using a cardiogenic small molecule, isoxazole (ISX-9) and their ability to grow in the scar tissue for functional improvement in the infarcted myocardium.
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
Cardiac stem cell therapy offers the potential to ameliorate postinfarction remodeling and development of heart failure but requires optimization of cell-based approaches. Cardiac progenitor cells (CPCs) induction by ISX-9, a small molecule possessing antioxidant, prosurvival, and regenerative properties, represents an attractive potentia
Cardiac stem cell therapy offers the potential to ameliorate postinfarction remodeling and development of heart failure but requires optimization of cell-based approaches. Cardiac progenitor cells (CPCs) induction by ISX-9, a small molecule possessing antioxidant, prosurvival, and regenerative properties, represents an attractive potential approach for cell-based cardiac regenerative therapy. Here, we report that extracellular vesicles (EV) secreted by ISX-9-induced CPCs (EV-CPCISX-9) faithfully recapitulate the beneficial effects of their parent CPCs with regard to postinfarction remodeling.
Pluripotent stem cell-induced skeletal muscle progenitor cells with givinostat promote myoangiogenesis
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart
Pluripotent stem cell-induced skeletal muscle progenitor cells with givinostat promote myoangiogenesis
Duchenne muscular dystrophy (DMD) is caused by mutations of the gene that encodes the protein dystrophin. A loss of dystrophin leads to severe and progressive muscle wasting in both skeletal and heart muscles. Human induced pluripotent stem cells (hiPSCs) and their derivatives offer important opportunities to treat a number of diseases. H
Duchenne muscular dystrophy (DMD) is caused by mutations of the gene that encodes the protein dystrophin. A loss of dystrophin leads to severe and progressive muscle wasting in both skeletal and heart muscles. Human induced pluripotent stem cells (hiPSCs) and their derivatives offer important opportunities to treat a number of diseases. Here, we investigated whether givinostat (Givi), a histone deacetylase inhibitor, with muscle differentiation properties could reprogram hiPSCs into muscle progenitor cells (MPC) for DMD treatment.
Media & Press
GIVI-MPC earns FDA orphan drug designation to treat DMD.
IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD
IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD
Source: Muscular Dystrophy News
IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD
IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD
IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD
Source: Muscular Dystrophy News
IPS HEART Aims to Use Induced Pluripotent Stem Cells to Treat Heart Attack
IPS HEART wins FDA rare pediatric drug designation for both stem cell therapies for DMD
FDA Grants Rare Pediatric Drug Designation for IPS Heart’s Stem Cell Therapy to Treat Cardiomyopathy Due to Danon Disease
Source: Biobanking
FDA Grants Rare Pediatric Drug Designation for IPS Heart’s Stem Cell Therapy to Treat Cardiomyopathy Due to Danon Disease
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate
FDA Grants Rare Pediatric Drug Designation for IPS Heart’s Stem Cell Therapy to Treat Cardiomyopathy Due to Danon Disease
Source: Global Genes, RARE Daily
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate
Source: Businesswire
IPS HEART receives FDA Rare Pediatric Drug Designations for both of its Stem Cell Drugs for Duchenne Muscular Dystrophy
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate
IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ISX9-CPC Stem Cell Therapy for Treatment of Cardiomyopathy Associated with Danon disease -Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidate
Source: Businesswire
FDA grants IPS HEART Orphan Drug Designation for GIVI-MPC for Treatment of Duchenne Muscular Dystrophy
Source: Businesswire
IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapy’s Ability to Create New Skeletal Muscle in Aged Mice
Source: Businesswire
IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy
IPS HEART Granted Orphan Drug Designation in the EU for Becker Muscular Dystrophy
Source: Businesswire